semaglutide lilly direct launches single-dose Zepbound to ease self-pay access Novo Nordisk cuts Ozempic price
Description
Obesity is a chronic, but treatable, disease associated with excess weight
Retrieved May 1, 2024, from Stevenson, R
The concern about semaglutide specifically traces back to a 2021 meta-analysis published in the Endocrine Journal
The maximum approved dose produces the greatest weight loss in clinical trials but also the highest side effect incidence
